EGFR and non-small cell lung carcinoma: Osimertinib, a 3rd generation of EGFR TKI, can overcome acquired T790M [31], and has also demonstrated superior activity as a first-line treatment for EGFR-mutant NSCLC with activating del19 and L858R mutation in the absence of T790M [32].